摘要
Objective： To study the effect and mechanism of Tianhuang Granule （田黄冲剂, THG） on hydrocephalus in the patients with acute cerebral hemorrhage （ACH） through intracranial pressure （ICP） monitoring, serum matrix metalloproteinase-9 （MMP-9） level observation, and National Institutes of Health Stroke Scale （NIHSS） scoring （for nerve function deficit）. Methods： Sixty patients with ACH were equally randomized into two groups by lottery, the control group and the THG group; all were treated with conventional therapy, but to the patients in the THG group, THG was given orally in addition for 28 days. Changes of ICP, MMP-9 expression, and NIHSS scores, as well as the degree of cerebral hematoma and hydrocephalus （by cranial CT scanning） in the patients, were estimated and compared. Results： （1） ICP was lowered more significantly in the THG group, showing a significant difference between groups on day 7 （P〈0.05）. （2） MMP-9 expression was down-regulated in the THG group more significantly and earlier than that in the control group. （3） The degrees of cerebral hematoma and hydrocephalus in the THG group on day 7 were reduced significantly as compared with those on day 3 （P〈0.05）, but in the control group, the day of significant reduction was delayed to day 14, and the degrees on day 7 and day 14 in the two groups were significantly different （P〈0.05 and P〈0.01）. （4） NIHSS score was significantly lower in the THG group than that in the control group on day 14 and day 28 （P〈0.05 and P〈0.01）. Conclusion： THG can effectively lower ICP, down-regulate MMP-9 expression, promote the absorption of cerebral hematoma and hydrocephalus, and improve the nerve function, showing a clinical effectiveness than conventional therapy.
Objective： To study the effect and mechanism of Tianhuang Granule （田黄冲剂, THG） on hydrocephalus in the patients with acute cerebral hemorrhage （ACH） through intracranial pressure （ICP） monitoring, serum matrix metalloproteinase-9 （MMP-9） level observation, and National Institutes of Health Stroke Scale （NIHSS） scoring （for nerve function deficit）. Methods： Sixty patients with ACH were equally randomized into two groups by lottery, the control group and the THG group; all were treated with conventional therapy, but to the patients in the THG group, THG was given orally in addition for 28 days. Changes of ICP, MMP-9 expression, and NIHSS scores, as well as the degree of cerebral hematoma and hydrocephalus （by cranial CT scanning） in the patients, were estimated and compared. Results： （1） ICP was lowered more significantly in the THG group, showing a significant difference between groups on day 7 （P〈0.05）. （2） MMP-9 expression was down-regulated in the THG group more significantly and earlier than that in the control group. （3） The degrees of cerebral hematoma and hydrocephalus in the THG group on day 7 were reduced significantly as compared with those on day 3 （P〈0.05）, but in the control group, the day of significant reduction was delayed to day 14, and the degrees on day 7 and day 14 in the two groups were significantly different （P〈0.05 and P〈0.01）. （4） NIHSS score was significantly lower in the THG group than that in the control group on day 14 and day 28 （P〈0.05 and P〈0.01）. Conclusion： THG can effectively lower ICP, down-regulate MMP-9 expression, promote the absorption of cerebral hematoma and hydrocephalus, and improve the nerve function, showing a clinical effectiveness than conventional therapy.
基金
Supported by the Special Fund for Integrative Chinese and Western Medical Researches of Tianjin City(No.07057)
